<DOC>
	<DOCNO>NCT02558868</DOCNO>
	<brief_summary>This study randomize , open-label , control study compare efficacy oxaliplatin combination irinotecan irinotecan alone second-line treatment patient gemcitabine S-1 refractory pancreatic cancer .</brief_summary>
	<brief_title>Second-Line Oxaliplatin Irinotecan Versus Irinotecan Alone Gemcitabine S-1 Refractory Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>Patients histologically confirm advanced pancreatic cancer experience progression firstline gemcitabine S1 eligible enrollment openlabel , randomize study . Additional inclusion criterion age 18 year older Measurable reference cancer site ( ) confirm compute tomography ( CT ) magnetic resonance imaging ( MRI ) Karnofsky performance status ( KPS ) least 70 % Adequate renal function , define creatinine clearance great 30 mL/min ) Adequate hepatic function , define asALT AST le 2.5× upper limit normal , liver metastasis , less 5_ upper limit normal Adequate bone marrow function , define platelet great 100×10E9/L WBC great 3.5×10E9/L . The presence severe concomitant disease could interrupt plan treatment ; intractable pain Hypersensitivity study drug Serious cardiovascular disease ( eg , unstable coronary artery disease myocardial infarction within 4 week study start ) National Cancer Institute CommonToxicity Criteria ( NCICTC ) grade 3 4 sensory motor neuropathy Prior concurrent malignancy ( pancreatic cancer ) Female , pregnancy breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>